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Head and neck cancer (HNC) is a complex and difficulttotreat malignancy that leads to 
severe disabilities and high mortality. We investigated if, after major improvements in 
diagnosis and therapeutic modalities, HNC survival has increased in Europe, and what 
are the main determinants of outcome. We found that survival from HNC remains low in 
Europe and, alongside with late stage at diagnosis, older age at diagnosis and smoking 
are strong predictors of outcome.  

+

Head and neck cancer (HNC) is a preventable malignancy that continues to cause 
substantial morbidity and mortality worldwide. Using data from the ARCAGE and Rome 
studies, we investigated the main predictors of survival after larynx, hypopharynx and 
oral cavity (OC) cancers. We used the KaplanMeier method to estimate overall survival, 
and Cox proportional models to examine the relationship between survival and 
sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC 
cancer cases were included in this study. Over a median followup time of 4.6 years, 
nearly 50% (n=586) of patients died. Fiveyear survival was 65% for larynx, 55% for OC, 
and 35% for hypopharynx cancers. In a multivariable analysis, we observed an increased 
mortality risk among older (≥71 years) vs. younger (≤50 years) patients with 
larynx/hypopharynx combined (LH) and OC cancers [HR=1.61, 95% CI 1.09–2.38 (LH) 
and HR=2.12, 95% CI 1.35–3.33 (OC)], current vs. never smokers [HR=2.67, 95% CI 
1.40–5.08 (LH) and HR=2.16, 95% CI 1.32–3.54 (OC)], and advanced vs. early stage 
disease at diagnosis [IV vs. I, HR=2.60, 95% CI 1.78–3.79 (LH) and HR=3.17, 95% CI 
2.05–4.89 (OC)]. Survival was not associated with sex, alcohol consumption, education, 
oral health, p16 expression, presence of HPV infection, or body mass index 2 years 
before cancer diagnosis. Despite advances in diagnosis and therapeutic modalities, 
survival after HNC remains low in Europe. In addition to the recognized prognostic effect 
of stage at diagnosis, smoking history and older age at diagnosis are important 
prognostic indicators for HNC.  
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Head and neck cancer (HNC) is mostly comprised of oral cavity, oropharynx, 
hypopharynx, and larynx tumors. When taken together, HNC represents the 5th most 
common malignancy in males in the highincome countries, with a lower incidence 
among females (male to female ratio varies from 2:1 to 4:1).1 Over 90% of cases are 
squamous cell carcinomas.2 HNC can be cured if the tumor is diagnosed at early stage 
and limited to the head and neck region. However, prognosis is very poor when HNC is 
diagnosed at later stages with metastatic or recurrent disease. A decision between 
aggressive multimodality and functionpreserving treatment should be based on patient’s 
health and comorbidities, and on the extent to which therapy may affect the patient’s 
quality of life.3  
 Tobacco exposure (including active and smokeless tobacco use) and alcohol 
consumption are wellestablished risk factors for HNC.4 Human Papillomavirus (HPV) 
infection is an additional independent risk factor for oropharynx cancer. Studies have 
shown that HPVrelated HNC is genetically and biologically different from smoking
associated HNC, with HPVrelated HNC demonstrating improved clinical outcomes.3 
HPV positive oropharynx cancer patients commonly have greater survival than HPV 
negative cases.57 However, the same HPV causal and prognostic associations have not 
been observed for larynx, hypopharynx, or oral cavity cancer where HPV infections are 
rare.8  
Stage at diagnosis has been considered one of the strongest predictors of survival 
among patients with HNC,9 whereas the role of smoking and alcohol on survival remains 
controversial. Robust epidemiological data may help to identify modifiable prognostic 
factors and guide cancer prevention programs aimed to reduce the burden of HNC 
worldwide.10 In this study we focused on the determinants of survival from larynx, 
hypopharynx, and oral cavity cancers in Europe. A separate study has examined survival 
from oropharynx cancer including the role of HPV.11  
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Data was obtained from 14 centers located in 9 European countries. Thirteen centers 
were participants of the ARCAGE* casecontrol study12 as follows: Czech Republic 
(Prague), Germany (Bremen), Greece (Athens), Italy (Aviano, Padova, and Turin), 
Ireland (Dublin), Norway (Oslo), United Kingdom (Glasgow, Manchester, and Newcastle), 
Spain (Barcelona), and Croatia (Zagreb). The remaining data were obtained from a case
control study in Rome.13 The recruitment of cases was performed from 2002 to 2005 for 
the ARCAGE study (n=1,066) and from 2003 to 2011 for the Rome study (n=144). 
Details of the ARCAGE and Rome projects can be found elsewhere.12,13  
 Cases eligible for inclusion in our study were all patients with a primary squamous 
cell carcinoma of the larynx, hypopharynx or oral cavity confirmed by histology or 
cytology. We included the following topography codes from the 

					 , 3rd edition (ICDO3)14: C320C32.9 for larynx, 
C12.9 and C13.0C13.9 for hypopharynx, and C00.3C00.9, C02.0C02.3, C03.0C03.9, 
C04.0C04.9, C05.0, and C06.0C06.9 for oral cavity cancers. Following a standard 
protocol, participants underwent an identical questionnairebased interview within 6 
months of diagnosis in order to obtain sociodemographic information, complete lifetime 
smoking and alcohol histories, dietary habits, dental health and care, and education level 
attained. Biological samples (blood and/or tumor blocks) were also collected. Data on 
stage at diagnosis, overall treatment, and clinical outcomes were subsequently obtained 
from populationbased registries, medical records, linkage with regional or national death 
index, as well as doctor’s contact. Participants were followed from the date of diagnosis 
to the date of death, loss to followup or end of study (31st December 2011), whichever 
occurred first. Patient’s followup was performed once from 2012 to 2015 to obtain last 
known vital status (alive, death, or lost to followup) and date of last contact.  

		
The sociodemographic, clinical and lifestylevariables were classified as follows. Age at 
diagnosis was categorized in 4 groups (≤50, 51–60, 61–70, and ≥71 years). Tumor stage 
at diagnosis was classified in stage I to IV based on the TNM system of the American 
Joint Commission on Cancer (AJCC) Staging Manual, 6th edition.15 Smoking was 
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examined in 3 different ways: overall history (never, former or current smokers), duration 
(never, 1–9, 10–19, 20–29, 30–39 and ≥40 years), or intensity (number of pack of 
cigarettes per year: never, <20, 20–39, 40–59, ≥60). Smokers were individuals who used 
any tobacco product (estimated based on cigarette equivalents) at least once a week for 
one year. Alcohol consumption was also examined in 3 ways: overall history (never, 
former or current drinkers), duration (never, 1–9, 10–19, 20–29, 30–39 and ≥40 years), 
and intensity (number of drinks per day: <5 or ≥5). Information on overall smoking and 
alcohol histories were obtained from all centers, whereas Rome did not have information 
on duration and intensity of these variables. Therefore, overall histories were included in 
the main models and separate models, excluding Rome cases, were performed to 
examine the effect of smoking and alcohol duration and intensity on survival, and were 
included in the supplementary materials (Table S1). 
 Education was categorized as level of education attained by the time of diagnosis: 
primary school, secondary school or university degree. Body mass index (BMI, kg/m2) 
was examined using selfreported height and weight 2 years before cancer diagnosis, 
which decreases the probability that low BMI is secondary to cancer development.16 BMI 
was classified according to the World Health Organization into 4 categories: underweight 
(<18.5), normal weight (18.5–24.9), overweight (25.0–29.9) and obese (≥30.0). Dental 
care and oral hygiene scores were created and classified as good, moderate, and poor 
as described elsewhere.17  
 Binary variables were sex (male/female) and the HPV tumor markers HPV16 DNA 
and p16 protein expression (positive/negative). HPV16 DNA genotyping was done using 
the typespecific E7 polymerase chain reaction beadbased multiplex assay (TSE7
MPG, IARC, Lyon, France) as described elsewhere.17 The qualitative assessment of 
antigen p16INK4A was performed by immunohistochemistry, using the CINtec Histology kit 
according to the manufacturer’s instructions (www.mtmlabs.com). P16 expression was 
scored based on the intensity and the proportion of nuclear and cytoplasmic stained 
cells, and was considered positive when the combined score was equal to 4 or higher. 
Studies have shown that combined p16 expression and HPV16 DNA testing are needed 
to predict outcome for HNC.18 We examined p16 expression alone and combined with 
HPV16 DNA as follow: p16 (–) DNA (–), p16 (+) DNA (–), p16 (+) DNA (+), and p16 (–) 
DNA (+). In addition to the variables above, we provided a descriptive analysis on 
relapse occurrence and overall treatment.  
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We used the KaplanMeier method to estimate 2, 5 and 8year overall (allcause) 
survival, and used the logrank test to examine differences in survival across strata of 
each variable. Overall survival is presented by anatomic site and, sample size allowing, 
by tumor subsite (glottis vs. supraglottis, tongue vs. other regions of the mouth, as well 
as pyriform sinus and other hypopharynx regions).  
 Multivariable Cox regression models were used to obtain the hazard ratios (HRs) 
of death and corresponding 95% confidence intervals (CI). We used the likelihood ratio 
test as an overall significance test for the association of each independent variable with 
the hazard ratio of death. We tested the proportional hazard (PH) assumption by 
examining loglog survival plots, and confirmed the results by using Schoenfeld’s global 
test. The PH assumption was met for all variables in the multivariable models. We 
included in the multivariable models the variables with  hypothesized or previously 
observed associations with survival (sex, age and stage at diagnosis, smoking and 
alcohol histories, BMI 2 years before diagnosis, education level, and dental care) and 
additionally adjusted for year of diagnosis. A separate model was performed to examine 
the association between HPV tumor markers and survival. 
 Given the modest number of hypopharynx cases, they were pooled with larynx 
cases for the multivariable analysis. When we performed separate Cox models, we 
observed the same pattern of associations for both larynx and hypopharynx cases, but 
with larger confidence intervals and pvalues for hypopharynx cases due to the smaller 
sample size. Cases from Rome did not provide data on education, BMI prediagnosis 
and oral health. Missing data were handled by including them as “unknown” categories in 
the multivariable models (omitted in the tables). A complete analysis where missing data 
were excluded was also conducted, and similar results were obtained. We tested for 
interactions between tumor sites and each variable and found no significant interaction. 
Statistical analyses were performed using Stata 14 software (StataCorp, College Station, 
TX, USA), and a 2sided pvalue of less than 0.05 was considered statistically significant. 



The ARCAGE study was approved by the Ethical Review Board of the International 
Agency for Research on Cancer (IARC), as well as the respective local boards in the 
individual participating centers. The Rome study was approved by the ethical committee 
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of Fondazione Policlinico Universitario “A. Gemelli”. All participants provided written  
informed consent for their participation in the study.   
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A total of 604 (50%) larynx, 146 (12%) hypopharynx and 460 (38%) oral cavity cancer 
cases were included in this study. The sociodemographic and clinical characteristics of 
patients are summarized by anatomic site in Table 1. Overall, most of patients were 
males (82%), ever smokers (91%), and ever drinkers (93%), had a median age at 
diagnosis of 60 years, and were diagnosed with advanced stage disease (55% stages III 
or IV vs. 45% stages I or II). 

	
The median followup time was 4.6 years. Of 1,210 patients, nearly half (n=586) died 
over the course of followup. Fiveyear survival was 65% for larynx (95% CI 61–69), 55% 
for oral cavity (95% CI 50–60) and 35% for hypopharynx (95% CI 27–43) cancers 
(Tables 2A & 2B, Figure1A). When an adequate sample size was available, survival was 
also examined by anatomic subsite. Based on the logrank test, we observed that 5year 
survival was higher among patients with glottic vs. supraglottic cancer (77% vs. 58%), 
and for those with tumor of the tongue vs. other regions of the mouth (63% vs. 50%). 
There was no evidence of difference in survival between patients with cancer of the 
pyriform sinus and other hypopharynx regions (Figures 1BD). 
 For all anatomic sites, we found strong evidence of an association between worse 
survival and smoking history (former or current smoker) (Tables 2A & 2B,) or advanced 
stage disease at diagnosis (Tables 2A & B, Supplementary Figure S1). Among oral 
cavity cancer patients, we also found associations of lower survival with older age at 
diagnosis, male sex, lower level of education, and low BMI 2 years before cancer 
diagnosis). There was no evidence of survival differences by p16 protein expression 
alone or combined with HPV testing for any cancer site (Table 2A & 2B). Survival did not 
vary by cancer center or country (data not shown). 


In a multivariable Cox regression analysis, in which all variables were mutually adjusted 
for, we found, among larynx/hypopharynx cases, an increased risk of death for 
hypopharynx vs. larynx cancer (HR=2.29, 95% CI 1.79–2.94), older compared to 
younger patients (≥71 vs. ≤ 50 years, HR=1.61, 95% CI 1.09–2.38), current vs. never 
smokers (HR=2.67, 95% CI 1.40–5.08) and advanced vs. early stage disease at 
diagnosis (IV vs. I, HR=2.60, 95% CI 1.78–3.79). Likewise, among oral cavity cancer 
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patients, we observed an increased risk of death for older compared to younger patients 
(≥71 vs. ≤ 50 years, HR=2.12, 95% CI, HR=1.35–3.33; and 61–70 vs. ≤ 50 years, 
HR=1.65, 95% CI 1.12–2.44), current vs. never smoker (HR=2.16, 95% CI 1.32–3.54), 
and for those with advanced vs. early stage at diagnosis (IV vs. I, HR=3.17, 95% CI 
2.05–4.89) (Table 3). We did not find significant associations between the risk of death 
and sex, dental care or BMI 2 years prediagnosis.  
 In separate analyses, when we used the number of packs of cigarettes smoked 
per year or duration of smoking instead of overall smoking history (Rome cases 
excluded), similarly strong associations were found. For instance, larynx/hypopharynx 
patients who smoked ≥20 cigarette pack years had approximately 3 times higher risk of 
death than never smokers. Likewise, for oral cavity cancer, patients who smoked ≥20 
cigarette pack years had a risk of death about 2.5 times higher than never smokers. 
(Supplementary Table S1) When we examined alcohol duration and intensity, we also 
did not find evidence of an association between the risk of death and alcohol 
consumption (Supplementary Table S1). There was no evidence of an association 
between the risk of death and p16 expression, whether examined alone or combined with 
HPV16 DNA testing (Figure 2, Supplementary Table S2).  

			
Data on relapse was available for approximately 80% of cases. Out of 973 patients, 341 
(35%) relapsed. Higher incidence of relapse was observed among patients with 
hypopharynx (46%), followed by oral cavity (38%) and larynx (30%) cancers (p=0.002). 
After excluding cases to whom relapse occurred less than 90 days from diagnosis 
(n=49), we observed that the majority of patients (n=194, 72%) relapsed within 2 years of 
HNC diagnosis, whereas 19% (n=52) and 9% (n=25) relapsed within >2 to 5 years and 
>5 to 10 years respectively (Supplementary Figure S2). Time to relapse did not differ 
significantly by anatomic site. 
 Overall information on type of treatment was available for approximately 97% of 
cases. Surgery was performed in most of patients (74%), alone (34%) or combined with 
radiotherapy (28%), chemotherapy (1%), or both (11%). About 12% of patients received 
radiotherapy alone, 10% received chemotherapy and radiotherapy, and 1% received 
chemotherapy alone. For about 2% of patients no type of treatment was reported. 

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Our results reveal that survival from head and neck cancer remains low in Europe. 
Except for patients with tumors of the glottis, 8year survival was lower than 50% for all 
tumor sites and subsites. In the multivariable analyses, the main predictors of survival 
were age at diagnosis, stage at diagnosis, smoking history, and anatomic site.  
Age at diagnosis is often considered an independent predictor of outcome for 
many types of cancer.19,20 The influence of age on HNC survival remains controversial. In 
a recent review, which included surgical, radiationalone, and chemoradiation studies 
from 1980 to 2012, the authors concluded that even though elderly patients may 
experience higher treatmentrelated toxicities than their younger counterparts, there was 
not sufficient evidence that survival is worse among older than younger patients (the 
majority of the studies investigated overall rather than diseasefree or cancerspecific 
survival).21 Another study which use data from the Surveillance Epidemiology and End 
Results (SEER) program in the United States (US) and estimated overall survival of 
patients diagnosed with larynx, tongue or tonsil cancer between 1988 and 1998, 
supported these findings.22  
In contrast,our findings of increased risk of death among older patients (≥71 years 
for larynx/hypopharynx and ≥61 years for oral cavity cancers) support the results of 
several populationbased studies in Europe and in the US. For instance, a European 
study used data from 15 French cancer registries on patients diagnosed with HNC 
between 1989 and 1997. The authors found that relative survival (which accounts for 
competing causes of death) was consistently lower for elderly compared to younger 
patients. The excess mortality among patients aged>75 years was apparent during the 
first 3 months and after 3 years of diagnosis, with no significant influence of age between 
1 and 3 years after diagnosis.23 Likewise, in a later European study on HNC, relative 
survival was lower among elderly (≥ 75 years) vs. younger patients diagnosed from 1999 
to 2007.9 In the US, a study from a large universitybased cancer registry used data from 
1990 to 2005 and found that, after adjusting for potential confounders, patients with HNC 
aged ≥70 years at diagnosis had a risk of death about twice as high as that of patients 
younger than 70 years.24 Notably, the authors showed that when older patients with 
advanced disease (stage at diagnosis III–IV) were treated with multimodality therapy, 5
year overall survival was close to that of younger patients who received similar 
therapeutic management. However, older patients who received singlemodality 
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treatment had dramatically lower 5year survival than their younger counterparts. Older 
age is commonly associated with moderate to severe comorbidities, which may diminish 
the patient’s ability to tolerate surgery and intensive cancer adjuvant treatment, such as 
radiotherapy and/or chemotherapy.10 Comorbidities such as cardiovascular and 
pulmonary diseases in HNC patients are mostly secondary to smoking and excessive 
alcohol use. In addition, advanced age is associated with a decline in immune function,25
27 which may not only facilitate cancer progression, but also weaken the host immune 
response against cancer.10 Nonetheless, studies suggest that, since cancer is the main 
cause of death among elderly patients with advanced HNC, the competing causes of 
death likely contribute to a small fraction of the lower survival observed among these 
patients.24 The main challenge in the treatment of elderly patients with HNC is to decide 
for which patients the benefit of intensive multimodality therapy compensates the risk of 
treatment toxicity.  
 Stage at diagnosis is widely considered a main determinant of cancer survival and 
this is also true for HNC.9 Our results showed that even with the advance on diagnosis 
procedures observed in the last decades, the majority of patients (55%) with HNC are 
still diagnosed with advanced disease (stage III–IV) in Europe. This proportion is close to 
the EUROCARE5 study,9 which used data from 29 European countries on patients 
diagnosed from 1999 through 2007. The authors emphasized that over 54% of patients 
were diagnosed with regional or metastatic disease. We found that the risk of death was 
approximately 2 or 3 times greater among patients with stage III or IV, respectively, than 
those with stage I at diagnosis. While HNC can be often cured when diagnosed at early 
stage, late stage disease may be untreatable or involve aggressive multimodality 
treatment that often leads to severe physical and psychological disabilities. It has been 
reported that HNC have the highest risk of disability and work quitting, together with 
central nervous system and hematologic malignancies28 
 We observed a strong association between smoking and survival. This association 
was significant for all investigated variables (overall smoking history, duration, and 
intensity) and highlights the importance of intensifying tobacco prevention and control in 
Europe. According to the World Health Organization, smoking kills closely 6 million 
people per year, more than HIV/AIDS, malaria and tuberculosis combined. It has been 
estimated that this number can increase to over 8 million people by 2030 if more 
immediate and severe actions are not taken.29 While some previous studies had shown 
negative30,31 or limited32,33 association between smoking and HNC survival, our findings 
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support a large populationbased study conducted in Ireland which revealed that smoking 
at diagnosis was associated with worse survival.34 The authors highlighted that this 
association was stronger among patients who had surgical treatment for their HNC, and 
neither chemotherapy nor radiotherapy influenced the effect of smoking on survival. One 
relevant question in the clinical setting is whether smoking cessation after cancer 
diagnosis can improve prognosis of HNC, for instance decreasing treatment 
complications and the risk of relapse or second primary malignancy.35 Posttreatment 
smoking history was not available in our study.  
 While our results support the influence of smoking on survival from HNC, we did 
not find the same association regarding alcohol consumption and survival when we 
examined overall alcohol history, duration or intensity. Our findings differ from a US 
study36 which found that alcohol consumption pre and postdiagnosis adversely affected 
HNC survival, and highlighted the need for aggressive interventions to help patients to 
abstain from or decrease alcohol intake. In another US study,37 which enrolled over 
1,000 patients with HNC, about 17% of patients had secondary tumors. Strikingly, 
alcohol consumption combined with smoking after diagnosis was found to significantly 
increase the risk of secondary tumors among these patients. More studies in Europe are 
needed to investigate the association between alcohol pre and postdiagnosis and HNC 
outcomes. 
 In our study, HNC prognosis varied significantly by anatomic site, with better 
survival for larynx, intermediate for oral cavity, and worse for hypopharynx cancer 
patients. These results are consistent with previous survival studies in Europe. For 
example, the EUROCARE II study,38 which used data from 17 countries on patients 
diagnosed from 1985 to 1989, revealed that overall, 5year relative survival was 
approximately 63% for larynx, 41% for oral cavity, and 22% for hypopharynx cancer, with 
wide geographic variations (higher survival in Western than Eastern European countries). 
The authors suggested that possible reasons for the observed survival disparities are 
late diagnosis, late referral to treatment, and lack of access to effective treatment. The 
subsequent EUROCARE5 study9 showed that 5year relative survival after larynx 
cancer has not improved over time (from 1999–2001 to 2005–2007), whereas survival 
improved by 3–5% (absolute difference) for oral cavity, oropharynx, and hypopharynx. 
However, 5year relative survival was still low: 25% for hypopharynx and 45% for oral 
cavity cancer patients. Although our results are not directly comparable, the same 
survival pattern was observed in our cohort of patients, suggesting no or little 
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improvement in the last few decades, despite progresses in diagnosis procedures and 
therapeutic management. This finding is concerning and emphasizes the need for 
increased healthcare policy aimed at decreasing modifiable risk factors (such as smoking 
and alcohol consumption) for HNC occurrence in Europe. 
 Curative treatment for HNC is complex and often negatively impacts patient's 
quality of life (e.g. causing difficulty to speak, breath, swallow, as well as facial 
deformity). Advancements in treatment such as new surgical techniques, the use of 
concurrent or alternating chemoradiation, hyperfractionated or accelerated radiotherapy, 
and more recently immunotherapy, may improve HNC survival and reduce the burden of 
complications secondary to treatment.39 However, improvement in HNC outcomes have 
been disappointing. Despite treatment advances, larynx cancer is one of the few types of 
cancer in which survival has recently decreased in the US (from 66% during 1975–1977 
and 1987–1989 to 63% during 2005–2011).40 It has been postulated that the declining 
survival trends are due to changes in treatment toward a nonsurgical (organ 
preservation) approach.41,42  
 For hypopharynx cancer, a recent populationbased study43 using SEER data 
showed evidence of increasing survival trends since 1990: 5year overall survival 
improved from 38% during 1973–1989 to 41% during 1990–2003. Through the study 
period, there was a trend toward reduced surgical treatment and increased use of 
radiationonly therapy. In contrast to what has been observed for larynx cancer in the US, 
this study suggests that organ preservation may have a survival benefit for hypopharynx 
cancer patients. For oral cavity cancer, surgery remains the firstline treatment,44 while 
radiotherapy and lymph node resection are usually performed for advanced stage 
disease or for those patients considered ineligible for surgical interventions. 
 It has been recognized that approximately 50% of patients with HNC have 
substantial weight loss at diagnosis and just before start of therapy in consequence of 
cancer symptoms (e.g. dysphagia, odynophagia, and anorexia),45 and this has been 
shown to negatively impact survival.46 Therefore, we aimed to investigate whether BMI 2 
years before diagnosis also influence survival after HNC. After multiple adjustments, we 
did not observe a significant association between the risk of death and underweight, 
which may be explained by the small number of patients in this category (fewer than 
3.5%). Likewise, overweight or obesity prediagnosis was not found to impact survival 
among our patients. 
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 Finally, when tumor samples were available, we evaluated whether p16 
expression alone or associated with HPV16 DNA testing predicts prognosis for non
oropharynx cancers. P16 is a tumor suppressor geneconsidered a good proxy for HPV 
infection in tumors.3 Our results support the lack of an association between survival and 
p16 overexpression examined alone, as reported by other authors.47,48 We also did not 
find any association with survival when p16 was considered with HPV16 DNA testing. It 
is possible that, in our study, the small number of HNC cases that were positive for both 
HPV16 DNA and p16 has contributed for the negative association we observed. Further 
studies to investigate the prognostic role of these markers on nonoropharynx cancer 
outcomes are warranted. 
 Our study has several limitations. Since the ARCAGE study was initially designed 
to look at risk factors of head and neck cancer, collection of clinical data such as detailed 
treatment approach and relapse (including dates of treatment and relapse) were 
restricted. Therefore it was not possible to investigate the impact of treatment modality 
on survival or relapse. We used selfreported weight and height 2 years before diagnosis, 
which may be subject to inaccuracy and bias. However, previous studies have shown 
high correlation (r>0.9) between selfreported and measured height, weight and BMI.49,50 
Overall, data were missing on stage at diagnosis in about 21% of cases. However, the 
strong association we found between stage at diagnosis and survival supports previous 
studies and emphasizes the impact of late diagnosis on HNC prognosis. Although Rome 
did not have information on certain variables, the data provided by this center were 
valuable and the associations we found remained even when these cases were excluded 
from the analyses. We also lacked information on comorbidities, performance status, and 
treatment complications. Although these data would likely have contributed additional 
findings, predictors of HNC outcome such as smoking, stage and age at diagnosis are of 
paramount importance and were clearly demonstrated in our study. In addition, the 
strengths of the ARCAGE study includes a standard protocol, data from several 
European centers with detailed information on smoking and alcohol histories, tumor 
histological or cytological confirmation for all patients, as well as blood and tumor 
samples for several cases.  
 In summary, HNC is a complex malignancy that involves vital anatomic structures, 
which make it difficult to treat. Surprisingly, despite the advances in diagnosis and 
therapeutic modalities, survival after HNC remains low in Europe. Most patients continue 
to be diagnosed with disease at advanced stage, which often requires aggressive 
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treatment and may lead to substantial disabilities and psychological disorders, reducing 
quality of life among survivors. The association between older age and inferior survival 
suggests that treatment should be personalized based on patients’ comorbidities and 
tolerability. Importantly, public health efforts in Europe should focus on primary 
prevention to deter the initiation of tobacco use, promote smoking cessation, and prevent 
excessive alcohol consumption. Furthermore, secondary prevention to detect HNC at an 
earlier stage is crucial. 
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Figure 1  Overall survival from head and neck cancers by: A, anatomic site; B, larynx subsite; C,  
hypopharynx subsite; and D, oral cavity subsite, 2002–2011, the ARCAGE study  
  
Figure 2  The hazard ratios of death by HPV16 tumor markers among patients with larynx,  
hypopharynx, and oral cavity cancers, 2002–2011, the ARCAGE study  
  
Figure S1: Overall survival from larynx, hypopharynx (combined), and oral cavity cancers by  
stage at diagnosis, 2002–2011, the ARCAGE study  
  
Figure S2: Number of patients with larynx, hypopharynx or oral cavity cancer who relapsed over  
time, 2002–2011, the ARCAGE study. Fortynine patients who relapsed within 90 days since  
diagnosis were excluded. 
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